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that is intended to be mixed with blood in a 4:1 ratio. 
Clearly, the same problem would occur with any other 
solution that uses our formulations to stop the heart and 
can be used safely as the warm reperfusate. 
Gerald D. Buckberg, MD 
University of California at Los Angeles 
School of Medicine 
Los Angeles, CA 90095-1741 
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Nitric oxide: Unjustified credit? 
To the Editor: 
We were interested to read of the experience of Mertes 
and associates, 1 because we have had similar experience 
with the use of inhaled nitric oxide for the implantation of 
the HeartMate 1000P left ventricular assist system 
(LVAS) (Thermo Cardiosystems, Inc., Woburn, Mass.). 
Our patient, similar to theirs, was 54 years old with 
end-stage idiopathic dilated cardiomyopathy but with 
additional renal and hepatic failure. We also had difficulty 
weaning the patient from cardiopulmonary b pass (CPB), 
being unable to increase the LVAS flows to more than 2 
L/min because of poor right ventricular function. The 
introduction of inhaled nitric oxide at a rate of 80 ppm 
resulted in immediate improvement of LVAS flow rates to 
more than 4 L/min and improvement in oxygenation, and 
CPB was subsequently successfully terminated. The effect 
of nitric oxide was demonstrated by a significant fall in 
LVAS flows (to 2.5 L/min) when inhaled nitric oxide was 
temporarily withdrawn (for change of cylinder and trans- 
port to the intensive care unit). Despite a subsequent 
promising 48-hour period when nitric oxide was able to be 
withdrawn, and despite LVAS flow rates of more than 5 
L/min, progressive hepatic and multiple organ failure 
developed, from which the patient died 2 weeks later. 
We are enthusiastic about he role of nitric oxide in this 
situation for a number of theoretical reasons. First, in- 
haled nitric oxide is specific to the pulmonary vasculature, 
giving rise to decreased pulmonary vascular esistance. 2 
This reduction in right ventricular afterload is likely to be 
of benefit in the management of postimplantation right 
heart failure provided that one can expect he pulmonary 
vascular esistance to decrease with time; this one would 
expect if the elevated resistance is caused by left ventric- 
ular dysfunction or if the resistance has been transiently 
exacerbated byperioperative blood transfusion. However, 
if the postimplantation right ventricular failure is due to 
poor preoperative right ventricular function or if there has 
been a perioperative decline in right ventricular function 
(i.e., poor myocardial protection), then the outlook for 
these patients may be poor and they may require the 
addition of a right ventricular assist device with all of its 
attendant risks. Additionally, in this situation of right 
ventricular failure, tricuspid regurgitation is almost inev- 
itable, and the reduced impedance to forward flow en- 
sures a smaller tricuspid regurgitant fraction and more 
elficient output from the dilated right ventricle. Second, 
unlike other vasodilators, nitric oxide has minimal sys- 
temic action because of rapid inactivation by hemoglobin. 3 
Third, the use of inhaled nitric oxide, in contrast to intrave- 
nous pulmonary vasodilators, improves perfusion of venti- 
lated alveoli and decreases the shuntfraction. 4 Last, unlike 
prostacyclin, inhaled nitric oxide has no demonstrable effect 
on hemostasis n vivo. In cases in which anticoagulation is 
unnecessary (as in the HeartMate LVAS), the lack of 
antihemostatic a tivity is an advantage. 
Having expressed our enthusiasm for inhaled nitric 
oxide on anecdotal nd theoretical grounds, we argue that 
the case presented by Mertes and associates I has insuffi- 
cient support for the conclusion that improvement was 
due to the use of inhaled nitric oxide. We are surprised to 
read that improvement occurred only after 30 minutes of 
nitric oxide administration ata rate of 50 ppm. From our 
experience, as well as other reports 5 of the use of inhaled 
nitric oxide in this and other situations (after transplan- 
tation and after mitral valve operations), we would have 
expected an almost immediate response. No further data 
to support he proposed effect of nitric oxide are offered, 
such as the effect of termination or interruption of nitric 
oxide. To the critical observer, the improvement may have 
been due to a spontaneous recovery in right ventricular 
function while the patient was supported by a further 
period of normothermic CPB, quite apart from delayed 
effects of concomitant treatment (e.g., diuretics, inodila- 
tors) that may have been additionally used. 
In summary, we share the nthusiasm for the use of 
inhaled nitric oxide in the management of right ventricu- 
lar failure after the insertion of a totally implantable 
LVAS. However, we do not accept he conclusion, on the 
data presented for this case, that inhaled nitric oxide was 
responsible for the improvement seen. In addition, al- 
though nitric oxide is extremely valuable in rapidly lower- 
ing pulmonary vascular esistance, unless the increased 
resistance is due to a reversible cause, the prospects for 
successful bridge to transplantation with an implantable 
LVAS alone may be poor. 
S. J. George, MRCP, FRCA 
J. J. M. BIack, FRCS 
M. J. Boscoe, FRCA 
Harefield, United Kingdorn 
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Fig. 1. One-way, valved, atrial septal patch. (From Luluaga IT, Yosifides de Luluagi I. Cierre gradual de 
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Reply to the Editor: 
The observations described by George, Black, and Boscoe 
are interesting. They appear to corroborate the beneficial 
effects of nitric oxide that my colleagues and I described-- 
reduction of acutely increased pulmonary vascular resistance 
after cardiopulmonary b pass (CPB) during implantation of 
a left ventricular assist system (LVAS). 
We would like to comment specifically on their question 
about the 30-minute delay that we observed before the 
beneficial effect of nitric oxide administration became 
apparent. 
We agree that nitric oxide administration is followed by 
a rapid (i.e., <5 minutes) decrease in pulmonary vascular 
resistance. In fact, we observed a rapid decrease in 
pulmonary artery pressure. However, inasmuch as our 
patient was supported by CPB, right ventricular preload 
was reduced, so that the LVAS could not fill completely 
and LVAS output was thus unable to increase signifi- 
cantly. However, peak LVAS filling volume rapidly in- 
creased, which onfirmed that the patient's hemodynamic 
status had improved. After almost 30 minutes the situa- 
tion appeared to be stable, with no further decrease in 
pulmonary vascular esistance or increase in pump filling 
rate. We completely agree that this beneficial effect was a 
combination of nitric oxide administration, which reduces 
right ventricular afterload, and possible recovery of right 
ventricular ~unction as a result of prolonged CPB. This 
was precisely what we hoped to achieve by waiting 30 
minutes with the patient supported by complete CPB. 
Nevertheless, when CPB support was progressively re- 
duced, so that right ventricular preload increased, the 
beneficial effects of a reduced right ventricular afterload 
became vident, as indicated by satisfactory LVAS output. 
Regarding the problem of demonstrating the beneficial 
effects of nitric oxide administration, we took great care to 
maintain an appropriate nitric oxide concentration when 
the patient was transported to the intensive care unit or 
when the cylinder was changed. 
Finally, George, Black, and Boscoe expressed concern 
regarding the poor prognosis of bridge to transplantation 
with an implantable LVAS alone in patients requiring 
nitric oxide administration. We still believe that this 
therapeutic approach allowed us to reduce the increase in 
pulmonary vascular esistance resulting from CPB, thus 
affording the possibility for progressive right ventricular 
recovery. This apparently was the case with our patient, 
who undelwent successful transplantation 3 months after 
LVAS implantation. 
Paul Michael Mertes, MD 
Service de Chirurgie Cardiaque et
Transplantations Cardio-Thoraciques 
CHU Nancy-Barbois 
Rue du Morvan 
Vandoeuvre les Nancy, France 
12/8/69340 
Valved atrial septal patch 
To the Editor: 
I read with interest he article of Ad and associates 1 
from the Beilinson and Tel-Aviv Medieal Centers on their 
experimental results achieved with a one-way, valved, 
atrial septal patch. The pateh was to be used in the 
management of postoperative right heart failure in pa- 
tients with congenital heart defects characterized by 
hypoplastic right ventricle or pulmonary hypertension. At 
the end of the article they suggested that a prospective 
clinical trial should be done. 
In 1967, Luluaga and Yosifides de Luluaga performed 
a similar operation to treat atrial septal defect with severe 
pulmonary hypertension i two patients, with uneventful 
recovery. The photograph of the patch (Fig. 1) is similar to 
that used in dogs by Ad and assoeiates. 
